Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 8/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29748711 | 0.90 | HSD17B1 (0.59) | KDM4ELMNAHSD17B10ACHEHSD17B1 | |
| SCHEMBL27661242 | 0.90 | HSD17B1 (0.59) | KDM4ELMNAHSD17B10ACHEHSD17B1 | |
| SCHEMBL9428615 | 0.89 | ACHE (0.66) | KDM4ELMNAHSD17B10SRD5A2ACHE | |
| SCHEMBL30574898 | 0.88 | KDM4E (0.71) | KDM4ELMNAHSD17B10ACHECA12 | |
| SCHEMBL226720 | 0.88 | KDM4E (0.71) | KDM4ELMNAHSD17B10ACHECA12 | |
| Water SCHEMBL4310345 | 0.86 | KDM4E (0.69) | KDM4ELMNAHSD17B10ACHEHSD17B1 | |
| SCHEMBL3468505 | 0.83 | HSD17B1 (0.58) | KDM4ELMNAHSD17B10ACHEHSD17B1 | |
| SCHEMBL9437164 | 0.81 | KDM4E (1.00) | KDM4ELMNAHSD17B10HSD17B1HSD17B2 | |
| SCHEMBL3468564 | 0.79 | CA1 (0.56) | KDM4ELMNAHSD17B10ACHEHSD17B1 | |
| SCHEMBL8050262 | 0.79 | P4HB (0.63) | KDM4ELMNAHSD17B10ACHEHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| CN-1856461-A | Cycloalkylene compounds as estrogen receptor modulators | SMITHKLINE BEECHAM CORP (US) | 2006-11-01 | — | — | CN | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | KDM4E 1543/4885LMNA 4708/4885HSD17B10 397/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | KDM4E 1543/4885LMNA 4708/4885HSD17B10 397/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | KDM4E 1738/4885LMNA 4504/4885HSD17B10 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.